Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Considering lifestyle and environment to maximize the economic value of R&D

Posted on November 10th, 2017 by in Pharma R&D

With an interest in systems approaches, I am always on the look-out for interesting papers in this area. A recent paper in Drug Discovery Today caught my eye for several reasons (1). The first was the extent of the problem with non-alcoholic liver disease. Continue reading “Considering lifestyle and environment to maximize the economic value of R&D” »

Start-Up Spotlight: XEPTAGEN

Posted on March 10th, 2017 by in Pharma R&D

Half the battle of treating a disease is to first diagnose it in a timely manner. XEPTAGEN, based in Venice, Italy, aims to develop effective, inexpensive tests to diagnose cancer and liver disease. Continue reading “Start-Up Spotlight: XEPTAGEN” »

Immune Checkpoints: New Promises in Cancer Treatment

Posted on October 26th, 2016 by in Pharma R&D

Cancer immunotherapy (especially checkpoint inhibitors) is hot in the cancer therapeutics world, but we are still learning about how best to use them and in which patients. The current explosion in new cancer immunotherapies relates to braking T-cell activation: checkpoint therapies. Continue reading “Immune Checkpoints: New Promises in Cancer Treatment” »

Women and minorities in clinical trials

Posted on September 16th, 2016 by in Pharma R&D

You are a female and/or a minority and concerned if you will respond to your medication. So you read the product label, asking yourself, “Do I see myself described as a patient in the drug testing trials?” Continue reading “Women and minorities in clinical trials” »

  1. 1
  2. 2
  3. 3